Zurcher Kantonalbank Zurich Cantonalbank trimmed its stake in shares of STERIS plc (NYSE:STE - Free Report) by 9.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 39,117 shares of the medical equipment provider's stock after selling 4,136 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in STERIS were worth $8,041,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Janney Montgomery Scott LLC grew its position in STERIS by 3.5% during the third quarter. Janney Montgomery Scott LLC now owns 7,609 shares of the medical equipment provider's stock valued at $1,846,000 after buying an additional 256 shares during the period. Principal Financial Group Inc. grew its position in shares of STERIS by 9.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider's stock valued at $270,230,000 after acquiring an additional 96,336 shares during the period. Axxcess Wealth Management LLC purchased a new stake in shares of STERIS in the 3rd quarter worth $203,000. Ashton Thomas Securities LLC bought a new position in STERIS in the 3rd quarter worth $25,000. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in STERIS by 0.8% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 220,866 shares of the medical equipment provider's stock worth $53,569,000 after purchasing an additional 1,706 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research analysts recently issued reports on STE shares. Piper Sandler boosted their price objective on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and issued a $240.00 price objective on shares of STERIS in a research note on Thursday, February 6th. Finally, JMP Securities restated a "market outperform" rating and set a $265.00 target price on shares of STERIS in a research report on Thursday, February 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $258.75.
Check Out Our Latest Stock Analysis on STERIS
STERIS Trading Up 0.5 %
STE stock traded up $1.21 during mid-day trading on Monday, reaching $227.84. The company had a trading volume of 416,186 shares, compared to its average volume of 500,637. STERIS plc has a 12 month low of $197.82 and a 12 month high of $248.24. The company has a market capitalization of $22.39 billion, a PE ratio of 48.37 and a beta of 0.92. The firm has a 50 day moving average of $219.17 and a 200 day moving average of $222.38. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40.
STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. On average, equities analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.
STERIS Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.57 per share. The ex-dividend date is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a yield of 1.00%. STERIS's dividend payout ratio is currently 48.41%.
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Articles
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
